RxDoctor Payments Data

Edmund Farris, MD

Ophthalmology · Harrison, NYNPI 1881646552

Payments from drug & device makers

$20,649in general payments, 2019–2025

Across 235 payments — averaging $87.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$7K
  • AbbVie$3K
  • Eyevance Pharmaceuticals LLC$3K
  • Alcon$2K
  • Lumenis BE Inc$2K
  • Harrow Eye, LLC$1K
  • plus $3K from 15 others

What the payments were for

  • Consulting fees$7,00034%
  • Speaking & faculty fees$5002%
  • Travel & lodging$6583%
  • Food & beverage$12,39560%
  • Education$960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,649 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$329,369
Medicare patients
868
Services billed
5,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost120$76,658
RestasisCyclosporine29$44,224
RocklatanNetarsudil Mesylat/Latanoprost34$31,793
CombiganBrimonidine Tartrate/Timolol32$11,769
Travoprost51$11,186
Cyclosporine16$10,661
SimbrinzaBrinzolamide/Brimonidine Tart33$10,242
VyzultaLatanoprostene Bunod18$9,366
RhopressaNetarsudil Mesylate20$8,040
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$6,725
Brinzolamide17$4,269
Latanoprost284$3,446
Brimonidine Tartrate40$3,038
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat152$2,991
Timolol Maleate94$2,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$3,241$132,651181 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$260$39,83354 claims
AlconSimbrinza$1,724$10,24233 claims
Bausch & Lomb Americas Inc.Vyzulta$72$9,36618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Harrison

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →